6221-12-1

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(2-bromoacetyl)pyridine is used as an intermediate for the synthesis of various pharmaceuticals, leveraging its reactivity to form complex organic molecules that can exhibit therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 3-(2-bromoacetyl)pyridine is utilized as a building block for the development of compounds that can be used in crop protection and other agricultural applications.
Used in Organic Chemistry Research:
3-(2-bromoacetyl)pyridine is employed as a reagent in organic chemistry for the functionalization and modification of other organic molecules, contributing to the advancement of chemical research and the discovery of new compounds with potential applications.

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 21970-14-9 pyridin-3-ylmagnesium bromide 
• 108-24-7 acetic anhydride 
• 60-29-7 diethyl ether 
• 6283-81-4 3-oxo-3-pyridin-3-yl-propionic acid ethyl ester 
• 39972-50-4 2-diazo-1-(pyridine-3-yl)ethan-1-one 

Downstream Products

• 139420-62-5 2-Amino-5-(3'-pyridyl)-6H-1,3,4-thiadiazine 
• 139420-57-8 2-Hydrazino-4-(3'-pyridyl)thiazole 
• 917903-62-9 2-{2-[3-(3-Piperidin-1-yl-Propoxy)-phenyl]-pyrrolidin-1-yl}-1-pyridin-3-yl-ethanone 
• 917904-79-1 2-{2-[3-(3-Morpholin-4-yl-propoxy)-phenyl]-pyrrolidin-1-yl}-1-pyridin-3-yl-ethanone 
• 1313013-77-2 N-(3-methyl-benzylidene)-N'-(8-morpholin-4-yl-2-pyridin-3-yl-imidazo[1,2-b]pyridazin-6-yl)-hydrazine 
• 1401198-00-2 3-(2-(5-(2,6-difluorophenyl)-3-phenyl-4,5-dihydropyrazol-1-yl)thiazol-4-yl)pyridine 
• 51746-85-1 3-(1H-imidazol-4-yl)pyridine 
• 1232035-81-2 [3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-(2-pyridin-3-yl-imidazo[1,2-a]pyridin-8-yl)amine 
• 194282-44-5 Pt((C₆H₅)2PCH₂CH₂P(C₆H₅)2)(S₂C₂HC₅H₄NH)⁽¹⁺⁾*BF₄^(1-)=[Pt((C₆H₅)2PCH₂CH₂P(C₆H₅)2)(S₂C₂HC₅H₄NH)]BF₄ 
• 1325216-23-6 6-(cyclohexyl(methyl)amino)-7-(4-(pyridin-3-yl)thiazol-2-ylamino)quinoxalin-2(1H)-one 
• 1310739-77-5 N-methyl-4-(4-(4-(pyridin-3-yl)thiazol-2-ylamino)phenoxy)picolinamide 
• 1290090-14-0 4-ethyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1290090-08-2 C₁₈H₁₇N₃O₂S 
• 1290090-13-9 N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 

Relevant academic research and scientific papers

Antiangiogenic and growth inhibitory effects of synthetic novel 1, 5-diphenyl-1,4 pentadiene-3-one-3-yl-ethanone pyridine curcumin analogues on Ehrlich ascites tumor in vivo

In the present investigation we have synthesized novel substituted dienone pyridine ethanone curcumin analogues 3a and 3b by nucleophilic substitution reactions with 2-bromo-1-pyridine-3-yl ethanone and characterized by 1H nuclear magnetic reso

Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors

A series of urea-based ROCK2 inhibitors were design and synthesized. The inhibitory activity on ROCK2 was screened by enzyme-linked immunosorbent assay (ELISA). The study results showed that the urea derivatives exhibited certain ROCK2 inhibitory activity. The most potent compound 10p showed ROCK2 inhibitory activity with the IC50?value of 0.03?μM. A preliminary structure-activity relationship was then summarized. The molecular docking studies showed that further optimization needs to conduct to obtain more potent ROCK inhibitors.

Synthesis, computational studies and antioxidant activity of some 3-(2-alkylamino-4-aminothiazole-5-oyl)pyridines

A series of thiazoloylpyridine derivatives has been synthesized and analyzed to confirm the structure of the product using IR,1H and13C NMR, mass spectra and analytical data. Optimized structural and electronic parameters of all the compounds have been calculated by using B3LYP/6-31G basis set. The Mulliken charges of all atoms have been evaluated. The calculated IR spectrum has been analyzed by comparing the experimental IR. All the synthesized compounds have been examined for antioxidant activities. The antioxidant activity of 3-(2-alkylamino-4-aminothiazol -5-oyl)pyridines have been analyzed using DPPH radical scavenging assay. The compounds 6a and 6b possess higher radical scavenging activity.

DYEING COMPOSITION, DYED PRODUCT, AND AZO COLORING AGENT

Provided are a dyeing composition which contains an azo coloring agent represented by Formula 1 or 2, a dyed product which is obtained by being dyed with the dyeing composition, and a novel azo coloring agent. In Formulae 1 and 2, C1 represents a heteroaromatic group, A1 and B1 each independently represent a heteroaromatic group, an aromatic group, or a group having a methine structure, and at least one of A1 or B1 represents a heteroaromatic group, D1 represents an anthraquinonyl group, and E1 represents a heteroaromatic group, an aromatic group, or a group having a methine structure. [in-line-formulae]A1-N═N—C1—N═N—B1??Formula 1[/in-line-formulae] [in-line-formulae]D1-N═N-E1??Formula 2[/in-line-formulae]

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B rece

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angiogenesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives

Steroidal and non-steroidal aromatase inhibitors target the suppression of estrogen biosynthesis in the treatment of breast cancer. Researchers have increasingly focused on developing non-steroidal derivatives for their potential clinical use avoiding steroidal side-effects. Non-steroidal derivatives generally have planar aromatic structures attached to the azole ring system. One part of this ring system comprises functional groups that inhibit aromatization through the coordination of the haem group of the aromatase enzyme. Replacement of the triazole ring system and development of aromatic/cyclic structures of the side chain can increase selectivity over aromatase enzyme inhibition. In this study, 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives were synthesized and physical analyses and structural determination studies were performed. The IC50 values were determined by a fluorescence-based aromatase inhibition assay and compound 1 (4-(2-hydroxyphenyl)-2-(pyrimidine-2-yl)thiazole) were found potent inhibitor of enzyme (IC50:0.42 nM). Then, their antiproliferative activity over MCF-7 and HEK-293 cell lines was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Compounds 1, 7, 8, 13, 15, 18, 21 were active against MCF-7 breast cancer cells. Lastly, a series of docking experiments were undertaken to analyze the crystal structure of human placental aromatase and identify the possible interactions between the most active structure and the active site.

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease

To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were identified. Selected compounds were also tested for neuroprotection in in vitro studies with PC-12 cells treated with 6-OHDA and rotenone, respectively. It was observed that some of the compounds tested yielded a marked increase in survival in PC-12 cells treated with the neurotoxins. This indicates that these propargylamines are able to confer protection against the effects of the toxins and may also be considered as novel disease-modifying anti-Parkinsonian agents, which are much needed for the therapy of Parkinson's disease.

Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system

Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.

HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.